Establishment of the new molecular therapy for refractory canine bladder transitional cell carcinoma expressed HER-2.

我们发现HER-2在犬膀胱移行细胞癌中的过表达率为100%。因此，我们开展了以HER-2为靶点的分子靶向治疗犬移行细胞癌的研究。对从犬病例中获得的移行细胞癌进行原代培养，并对培养的细胞进行性质分析。结果，建立了三个移行细胞癌细胞系。HER-2基因和蛋白在三种细胞系中均有表达。然而，作为抗癌药敏感性检查的结果，抗HER-2药物曲妥珠单抗未显示出对移行细胞癌的细胞毒性。 体外评价表明，曲妥珠单抗对犬移行细胞癌的抗肿瘤作用之一需要免疫系统应答。需要进一步的研究来探索这种反应。

We found that HER-2 overexpressed at the rate of 100% for canine bladder transitional cell carcinomas. Therefore we carried out research using molecular target therapy that targeted HER-2 as a new treatment for canine transitional cell carcinoma. Primary culturing of the transitional cell carcinoma obtained from canine cases was performed, and property analysis of the cultured cells was performed. As a result, three transitional cell carcinoma cell lines were established. The appearance of gene and protein expression of HER-2 was found for all three cell lines. However, as a result of the anticancer agent sensitivity examination, the anti-HER-2 agent, trastuzumab did not show cell cytotoxicity for transitional cell carcinomas. In vitro evaluation suggested that one of the antitumor effects of trastuzumab for canine transitional cell carcinomas requires an immune system response. Further study is needed to explore this response.